ROR1 and breast carcinoma: It has demonstrated safety and efficacy in Phase I/II clinical trials for a number of ROR1-expressing malignancies, including chronic lymphocytic leukemia (CLL) [11,12], mantle cell lymphoma (MCL) [13] and Her2-negative breast cancer (NCT02776917).